Amferia today announced the close of an oversubscribed €3.5 million investment round.
The new funding—led by both existing shareholders and several new investors prominent in global wound care—will accelerate clinical development in human health, scale Amferia’s growing animal-health business, and support commercialization of new products based on its proprietary antimicrobial peptide (AMP) hydrogel platform.
This investment follows a milestone year in which Amferia introduced Europe’s first veterinary wound dressing using antimicrobial peptides, launched in collaboration with leading animal-health partners, and advanced its U.S. regulatory pathway for human wound care.
Fueling Growth Across Human and Veterinary Medicine
According to Amferia CEO and co-founder Anand Rajasekharan, the new financing will help the company advance clinical development toward CE marking and FDA clearance for human health applications in Europe and the United States, as well as expand Amferia’s animal-health footprint in Europe, where the company has already secured commercial agreements with Orkla Wound Care AB and Biokema SA.
“This funding will allow us to continue battling antibiotic-resistant bacteria and speed wound recovery in both human and animal patients,” Rajasekharan said.
“Amferia aims to broaden the new tools we offer clinicians to fight infection and reduce unnecessary antibiotic use. We hope to scale manufacturing and commercialization of our anti-microbial wound-care solution pipeline and broaden the platform to include applications such as surgical materials, implant sterilization, and deep-wound sprays.”
Read the full press release here
Read the piece by the Swedish newspaper Dagens Industri here
